home / stock / polbf / polbf news


POLBF News and Press, Poolbeg Pharma plc Ord GBP 0.0002 From 09/21/22

Stock Information

Company Name: Poolbeg Pharma plc Ord GBP 0.0002
Stock Symbol: POLBF
Market: OTC
Website: poolbegpharma.com

Menu

POLBF POLBF Quote POLBF Short POLBF News POLBF Articles POLBF Message Board
Get POLBF Alerts

News, Short Squeeze, Breakout and More Instantly...

POLBF - Poolbeg Licence of Melioidosis Vaccine Candidate

Targeting an infectious disease with a high mortality rate and growing incidence driven by climate change LONDON, UK / ACCESSWIRE / September 21, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company wit...

POLBF - Poolbeg Pharma PLC Announces HC Wainwright Global Investment Conference

LONDON, UK / ACCESSWIRE / September 12, 2022 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that the Company's Chairman, Cathal Friel, will be attending th...

POLBF - Poolbeg Pharma PLC Announces Appointment of Joint Broker

LONDON, UK / ACCESSWIRE / July 29, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has appointed Singer Capital Markets as Joint Broker with immediate effe...

POLBF - Poolbeg Pharma PLC Announces POLB001 Human Challenge Clinical Trial To Commence

Major milestone reached as POLB 001 human challenge clinical trial ready to commence Regulatory approval gives green light for trial to proceed LONDON, UK / ACCESSWIRE / July 20, 2022 / Poolbeg Pharma (Poolbeg Pharma plc) (AIM:POLB)(OTCQB:POLBF), ('Poolbeg' or the 'Company'), a...

POLBF - Poolbeg Pharma PLC Announces Project update for AI model of RSV data

OneThree Biotech completes build and optimisation of AI model for RSV data - results to come in H2 First time AI used to model RSV with complete longitudinal disease data LONDON, UK / ACCESSWIRE / June 27, 2022 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, 'Poolbeg' or the 'Company'),...

POLBF - Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23 r d Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOG...

POLBF - UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd 

NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23 rd . Individual inve...

POLBF - Life Sciences Investor Forum: Company Executives Present Live June 23rd 

NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23 rd . Individual inve...

POLBF - Poolbeg Pharma PLC Announces US Patents Granted for POLB 001 and POLB 002

Further Expansion of IP Portfolio Enhancing Protection of Poolbeg's Growing Pipeline LONDON, UK / ACCESSWIRE / May 26, 2022 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a unique capital lig...

POLBF - Poolbeg Pharma PLC - GMP Manufacturing Contract Signed

Update on POLB 001 Clinical Development GMP manufacturing contract signed ensuring ample supply of POLB 001 for clinical development and for use in investigating further potential disease indications LONDON, UK / ACCESSWIRE / May 12, 2022 / Poolbeg Pharma (AIM:POLB), (OTCQB:POLBF), ...

Previous 10 Next 10